We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+139.21%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.3B
AUM Growth
+$1.62B
Cap. Flow
+$431M
Cap. Flow %
13.06%
Top 10 Hldgs %
71.48%
Holding
41
New
9
Increased
7
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$91.7M
2
ETNB
89bio
ETNB
+$88M
3
ARVN icon
Arvinas
ARVN
+$58.8M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$56.2M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$44.4M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$35.3M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$32.1M
3
DTIL icon
Precision BioSciences
DTIL
+$15.5M
4
KOD icon
Kodiak Sciences
KOD
+$14.7M
5
AXSM icon
Axsome Therapeutics
AXSM
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 95.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THOR
1
DELISTED
Synthorx, Inc. Common Stock
THOR
$680M 20.61%
9,724,598
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$582M 17.66%
4,185,342
+52,900
+1% +$5.88M
RARX
3
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$228M 6.91%
4,858,260
– –
ARVN icon
4
Arvinas
ARVN
$530M
$151M 4.58%
3,672,872
+2,009,360
+121% +$58.8M
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
$127M 3.84%
+3,199,389
New +$56.2M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.31B
$124M 3.78%
5,422,312
+2,000,000
+58% +$44.4M
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$124M 3.76%
2,162,671
– –
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$118M 3.57%
2,260,751
– –
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$928M
$114M 3.44%
+3,646,808
New +$91.7M
TGTX icon
10
TG Therapeutics
TGTX
$8.19B
$110M 3.33%
9,880,323
+3,000,000
+44% +$22.8M
STSA
11
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$92.1M 2.79%
4,681,858
– –
ORTX
12
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$87.9M 2.66%
638,990
+116,542
+22% +$14.2M
ETNB
13
DELISTED
89bio
ETNB
$83.1M 2.52%
+3,161,214
New +$88M
FTSV
14
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$76.1M 2.31%
+1,933,250
New +$31.1M
WVE icon
15
Wave Life Sciences
WVE
$1.12B
$62.3M 1.89%
7,775,207
– –
TVTX icon
16
Travere Therapeutics
TVTX
$5.17B
$60.4M 1.83%
4,252,453
+264,893
+7% +$3.38M
BOLD
17
DELISTED
Audentes Therapeutics, Inc
BOLD
$54M 1.64%
+902,383
New +$33.9M
PRVL
18
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$53.2M 1.61%
3,363,605
– –
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$8.88B
$47M 1.43%
1,875,209
– –
ARDX icon
20
Ardelyx
ARDX
$1.24B
$40.2M 1.22%
+5,358,863
New +$32.6M
AXSM icon
21
Axsome Therapeutics
AXSM
$11.7B
$38M 1.15%
367,816
-296,569
-45% -$12M
IGMS
22
DELISTED
IGM Biosciences
IGMS
$37.5M 1.14%
982,723
+516,355
+111% +$13M
STOK icon
23
Stoke Therapeutics
STOK
$1.84B
$31.7M 0.96%
1,119,963
– –
RLMD icon
24
Relmada Therapeutics
RLMD
$540M
$29.7M 0.9%
+761,666
New +$23.1M
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$28.5M 0.87%
+1,445,801
New +$23.1M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, RA Capital Management held 41 positions worth $3.3B, up 96% from $1.68B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

RA Capital Management deployed $431M of net new capital in Q4 2019, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Phathom Pharmaceuticals: 3,646,808 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $12M trimmed.

  • RA Capital Management's largest Q4 2019 buy was Phathom Pharmaceuticals: 3,646,808 shares worth $114M.
  • RA Capital Management added most to Arvinas in Q4 2019, an estimated $58.8M increase.
  • RA Capital Management's biggest Q4 2019 reduction was Axsome Therapeutics, cutting an estimated $12M.
  • RA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2019, selling an estimated $35.3M.
  • RA Capital Management's ten largest holdings make up 71% of its $3.3B portfolio in Q4 2019.
  • RA Capital Management opened 9 new positions and closed 7 in Q4 2019.
  • RA Capital Management's portfolio value rose 96% quarter-over-quarter to $3.3B.

Based on RA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.